Zvika LTC - DNA Biomed VP Programs
| DNA Stock | ILS 106.00 3.50 3.20% |
Insider
Zvika LTC is VP Programs of DNA Biomed Solns
| Phone | 972 3 970 5000 |
| Web | https://www.laser-detect.com |
DNA Biomed Management Efficiency
The company has return on total asset (ROA) of (0.0375) % which means that it has lost $0.0375 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2509) %, meaning that it generated substantial loss on money invested by shareholders. DNA Biomed's management efficiency ratios could be used to measure how well DNA Biomed manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Batel LachmiCohenl | Amot Investments | 38 | |
| Maya Grinfeld | ICL Israel Chemicals | N/A | |
| Nir Sarfatty | YD More Investments | N/A | |
| Sammy Bassat | Harel Insurance Investments | 76 | |
| Oranit Shaya | YD More Investments | 53 | |
| Uri Schor | Harel Insurance Investments | N/A | |
| Elad Aharonson | ICL Israel Chemicals | 49 | |
| Tzipi OzerArmon | ICL Israel Chemicals | 53 | |
| Alon Eliraz | Harel Insurance Investments | 52 | |
| Aya Landman | ICL Israel Chemicals | N/A | |
| Larissa Cohen | Discount Investment Corp | 46 | |
| Amir Meshulam | ICL Israel Chemicals | 43 | |
| Nitzan Moshe | ICL Israel Chemicals | 52 | |
| Doron Cohen | Discount Investment Corp | 63 | |
| Nir Cohen | Harel Insurance Investments | 52 | |
| Ron Sirani | YD More Investments | N/A | |
| Yosi Levy | YD More Investments | 65 | |
| Aviram Lahav | ICL Israel Chemicals | 64 | |
| Rotem Zeirel | YD More Investments | 37 | |
| Lilach GevaHarel | ICL Israel Chemicals | 43 | |
| Noam Goldstein | ICL Israel Chemicals | 62 | |
Management Performance
| Return On Equity | -0.25 | |||
| Return On Asset | -0.0375 |
DNA Biomed Solns Management Team
Elected by the shareholders, the DNA Biomed's board of directors comprises two types of representatives: DNA Biomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DNA. The board's role is to monitor DNA Biomed's management team and ensure that shareholders' interests are well served. DNA Biomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DNA Biomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Gaft, Chief Scientist | ||
| Tony Klein, Vice President - Finance | ||
| Zvika LTC, VP Programs |
DNA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DNA Biomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.0375 | |||
| Current Valuation | 59.57 M | |||
| Shares Outstanding | 123.16 M | |||
| Shares Owned By Insiders | 54.87 % | |||
| Price To Earning | 22.59 X | |||
| Price To Book | 0.95 X | |||
| EBITDA | 18.42 M | |||
| Net Income | 18.37 M | |||
| Cash And Equivalents | 492 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in DNA Stock
DNA Biomed financial ratios help investors to determine whether DNA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DNA with respect to the benefits of owning DNA Biomed security.